Targeting the IL-4 pathway in T-ALL patients

Wouter Sleeckx, a doctoral researcher at the University of Ghent, presented his research on the therapeutic potential of targeting the IL-4 signalling pathway in a subset of T-ALL patients. His study focuses on patients harbouring genomic aberrations that drive abnormal IL-4 receptor expression that can be activated by paracrine IL-4 present in the microenvironment or acquire the ability to produce and excrete autocrine IL-4.